The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The global mycoplasma testing industry’s growth is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R & D activities and investments. The assays, kits, & reagents segment accounted for the highest growth rate in the mycoplasma testing market, by product, during the forecast period “ The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service.In 2019, the assays, kits, & reagents segment accounted for this market’s largest share.
The frequent purchase of these consumables compared to instruments and the increasing use of kit-based techniques for mycoplasma testing are the important factors driving the growth of this market segment.
Cell line testing segment accounted for the highest CAGR Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing.In 2019, the cell line testing segment accounted for the largest share of this market.
Factors such as the rapid growth in the biopharmaceutical industry and the increasing demand for monoclonal antibodies drive this market segment’s growth.
Asia Pacific: The fastest-growing region mycoplasma testing market The Asia Pacific mycoplasma testing market is estimated to grow at the highest CAGR during the forecast period. This can primarily be attributed to the expansion of key market players in emerging Asian countries, increasing expenditure on life science research in the region, and the increasing trend of pharmaceutical outsourcing to Asian countries such as India and China.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 20%, Tier 2 - 45%, and Tier 3 - 35% • By Designation: C-level - 30%, D-level - 20%, and Others - 50% • By Region: North America - 36%, Europe - 25%, Asia Pacific - 27%, and Rest of the World – 12%
List of companies profiled in the report: • Thermo Fisher Scientific, Inc. (US) • Charles River Laboratories International, Inc. (US) • Lonza Group Ltd. (Switzerland) • Merck KGaA (Germany) • Roche Diagnostics (Switzerland) • American Type Culture Collection (US) • Bionique Testing Laboratories, Inc. (US) • InvivoGen (US) • PromoCell GmbH (Germany), • Biological Industries Israel Beit Haemek Ltd. (Israel) • Creative Bioarray (US) • Mycoplasma Experience (UK) • Norgen Biotek Corp. (Canada) • Agilent Technologies (US) • Biotools B & M Labs, S.A. (Spain) • Eurofins Scientific (Luxembourg) • GeneCopoeia, Inc. (US) • GenBio (Canada) • Minerva Biolabs GmbH (Germany) • Meridian Bioscience, Inc. (US) • Sartorius AG (Germany) • Savyon Diagnostics (Israel) • Nelson Laboratories Fairfield, Inc. (US) • Clongen Laboratories, LLC (US) • ScienCell Research Laboratories, Inc. (Canada).
Research Coverage: This report provides a detailed picture of the global mycoplasma testing market.It aims at estimating the size and future growth potential of the market across different segments, such as product, technique, application, end user, and region.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mycoplasma testing market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and trends.
Our reports have been used by over 10K customers, including:
224 pages •
By The Business Research Company
• Dec 2020
Next Generation Sequencing Global Market Opportunities And Strategies 2020-30: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global next generation sequencing market. Description: Where is the largest and fastest growing...
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
Retrovirus Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Retrovirus Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Retrovirus Tests pipeline products with comparative analysis of the products at various stages...
The Asia Pacific cancer vaccines market was valued at US$ 861.55 million in 2019 and is projected to reach US$ 3,131.09 million by 2027; it is expected to grow at a CAGR of 17.9% during 2020–2027. Demand for cancer vaccines is expected to increase in the forecast period due to factors such as growing incidences of human papillomavirus...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global dPCR and qPCR Market Report The dPCR and qPCR market by revenue is expected to grow at a CAGR of over 9% during the period 2020–2025. The global digital PCR (dPCR) and the real-time PCR (qPCR) market is one of the dynamic and fast-growing...
Bacteriology Rapid Tests and POC - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Bacteriology Rapid Tests and POC - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Bacteriology Rapid Tests & POC pipeline products with comparative...